The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VIII.a

Angioedema (may cause UAO, asphyxia and death)

Publications

Liu Q, Cui Z, Deng C, Yang C, Shi T

A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases.

Frontiers in pharmacology. 2024;15:1485190

Soo Hoo GW, Lin HK, Junaid I, Klaustermeyer WB

Angiotensin-converting Enzyme Inhibitor Angioedema Requiring Admission to an Intensive Care Unit.

The American journal of medicine. 2015;128(7):785-9

Strassen U, Bas M, Hoffmann TK, Knopf A, Greve J

Treatment of angiotensin receptor blocker-induced angioedema: A case series.

The Laryngoscope. 2015;125(7):1619-23

Montoro de Francisco A, García-Luque A, Fernández M, Puerro M

Side effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: are we facing a new syndrome.

The American journal of cardiology. 2012;110(10):1552-3